742 related articles for article (PubMed ID: 28190259)
21. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
22. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Florman S; Vincenti F; Durrbach A; Abouljoud M; Bresnahan B; Garcia VD; Mulloy L; Rice K; Rostaing L; Zayas C; Calderon K; Meier-Kriesche U; Polinsky M; Yang L; Medina Pestana J; Larsen CP
Clin Transplant; 2018 Apr; 32(4):e13225. PubMed ID: 29461660
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
[TBL] [Abstract][Full Text] [Related]
24. Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes.
Tremblay S; Kaiser TE; Alloway RR; Woodle ES; Diwan TS
Prog Transplant; 2016 Jun; 26(2):183-90. PubMed ID: 27207408
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
[TBL] [Abstract][Full Text] [Related]
26. Conversion to belatacept within 1-year of renal transplantation in a diverse cohort including patients with donor-specific antibodies.
Santeusanio AD; Bhansali A; Weinberg A; Shapiro R; Delaney V; Florman S; De Boccardo G
Clin Transplant; 2020 Apr; 34(4):e13823. PubMed ID: 32049378
[TBL] [Abstract][Full Text] [Related]
27. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
[TBL] [Abstract][Full Text] [Related]
28. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient.
Zmonarski S; Madziarska K; Banasik M; Mazanowska O; Magott-Procelewska M; Hap K; Krajewska M
Transplant Proc; 2018; 50(6):1744-1749. PubMed ID: 30056893
[TBL] [Abstract][Full Text] [Related]
29. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
[TBL] [Abstract][Full Text] [Related]
30. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
32. Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function.
Ravindra KV; Sanoff S; Vikraman D; Zaaroura A; Nanavati A; Sudan D; Irish W
Am J Transplant; 2019 Mar; 19(3):781-789. PubMed ID: 30171800
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
[TBL] [Abstract][Full Text] [Related]
34. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study.
Cohen JB; Eddinger KC; Forde KA; Abt PL; Sawinski D
Transplantation; 2017 Oct; 101(10):2582-2589. PubMed ID: 27941427
[TBL] [Abstract][Full Text] [Related]
35. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis.
Schwarz C; Mayerhoffer S; Berlakovich GA; Steininger R; Soliman T; Watschinger B; Böhmig GA; Eskandary F; König F; Mühlbacher F; Wekerle T
Transpl Int; 2015 Jul; 28(7):820-7. PubMed ID: 25703346
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
39. Impact of Belatacept Conversion on Renal Function, Histology, and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection.
Kumar D; Raynaud M; Chang J; Reeve J; Yakubu I; Kamal L; Levy M; Bhati C; Kimball P; King A; Massey D; Halloran P; Gupta G
Transplantation; 2021 Mar; 105(3):660-667. PubMed ID: 32510913
[TBL] [Abstract][Full Text] [Related]
40. Risk factors and outcomes of prolonged recovery from delayed graft function after deceased kidney transplantation.
Zhang H; Fu Q; Liu J; Li J; Deng R; Wu C; Nie W; Chen X; Liu L; Wang C
Ren Fail; 2020 Nov; 42(1):792-798. PubMed ID: 32772773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
